HHS, DOD award $481M for point-of-care COVID-19 test, announce vaccine manufacturer partnership
The Department of Health and Human Services and the Department of Defense yesterday awarded $481 million to Cue Health Inc. to expand production of a point-of-care COVID-19 molecular test with capabilities to produce results in 20 minutes.
Cue said the highly sensitive test uses a nasal swab sample to detect RNA of SARS-CoV-2, the virus that causes COVID-19. HHS said the partnership allows Cue to increase production to 100,000 test kits per day by March 2021.
Also yesterday, HHS and DOD announced a separate, $31 million agreement with Cytiva to expand the company’s capacity to produce items essential to the production of COVID-19 vaccines such as liquid and dry powder cell culture media, cell culture buffers, mixer bags, and bioreactors.
Related News Articles
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…